1F7 Shows Positive Data for Hepatitis C

[Guest guest]

Immune Network: 1F7 Shows Positive Data for Hepatitis C: Data

published in Journal of Medical Virology

VANCOUVER, B.C.--(BUSINESS WIRE)--Jan. 8, 2002--Immune Network Ltd.

(OTCBB:IMMKF)(CDNX:IMM.) announced today the publication of results

with its 1F7 antibody in tests designed to find out whether it may be

able to improve the response of the immune system to infection.

The 1F7 antibody is thought to have specific reactivity with

antibodies from both the human immunodeficiency (HIV) and the

hepatitis C (HCV) viruses.

" As others have previously demonstrated for HIV, we now show that

antibodies against HCV share a common structural feature recognized

by 1F7, " said Dr. Grant, a member of the immunology research

group in the Faculty of Medicine at Memorial University in Canada and

collaborator with Immune Network. " It's reasonable to speculate that

antibodies produced in other chronic diseases share the same

features. " Dr. Grant has shown that 1F7 selectively binds antibodies

against multiple components of HCV in addition to previous studies

showing the binding of 1F7 to anti-HIV antibodies. This is exciting

news, since it means that 1F7 has the potential to boost the human

immune system when either or both infections are present. Further

work is planned with 1F7 to test for its reactivity with antibodies

to other viruses causing chronic infections, to further establish its

mechanism of action, and to develop it as a potential human

therapeutic drug.

The Journal of Medical Virology published Dr. Grant's work under the

title " Antibody Convergence Along a Common Idiotypic Axis in

Immunodeficiency Virus and Hepatitis C Virus Infections " in its

January issue. The abstract can be viewed on the World Wide Web at

http://www3.interscience.wiley.com/cgi-bin/abstract/88511251/START .

Copies of the abstract and the complete publication can also be

obtained from Immune Network. This work was funded by Immune Network

and by the Canadian Institute for Health Research.

More about 1F7:

Monoclonal antibody 1F7 has profound effects on the function of the

immune system and the action of immune cells. Numerous publications

suggest that 1F7 may be able to extend the ability of the immune

system to generate antibodies against HIV, even after the virus

mutates, possibly preventing the virus from " escaping " from the

immune system. Other data from Dr. Grant's laboratory, published in

Immunology and Cell Biology in February 2000, demonstrated that 1F7

had specific effects on human immune cells (CTL cells) from HIV

infected patients to prevent these cells from killing other immune

cells (uninfected helper T cells).

If the beneficial effects of 1F7 on the immune system can be

confirmed, it would be an important new approach to the treatment of

HIV infection and AIDS. Now, with the demonstration that 1F7 has

activity that could have an impact on other chronic viral diseases

such as HCV, the relevance of accelerating the development of 1F7 is

evident. Immune Network is forming a team in 2002 to develop a plan

for the clinical evaluation and future commercialization of this

product as well as that of another Immune Network anti-HIV antibody,

hNM01. Further information on these products and the team working on

them will be available later in this quarter.

On behalf of the Board of Directors

Bain, Ph.D., CEO

" Safe Harbor " Statement under the Private Securities Litigation

Reform Act of 1995:

This news release contains forward looking statements that are not

historical facts and are subject to risks and uncertainties which

could cause actual results to differ materially from those set forth

in or implied herein. These risks are described in detail in the

company's Securities and Exchange Commission filings.

The Canadian Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of the content of this

news release.

CONTACT:

Immune Network Ltd.

Investor Relations, 604/222-5541

or 1-877/644-5541 ext. 466

Fax: 604/222-5542

E-mail: info@...

Website: www.immunenetwork.com

__________________________________________________

[Guest guest]

Hi Claudine...this is very intersting...at least Vancouver is trying

to do something about HCV...which makes me feel better. My pc doc

asked me if I wanted to go to UBC for the trials, but it's too far

away from me. It is an option however, and I will keep it in mind.

Thanks

Carol

claudine intexas wrote:

>

> Immune Network: 1F7 Shows Positive Data for Hepatitis C: Data

> published in Journal of Medical Virology

>

>

> VANCOUVER, B.C.--(BUSINESS WIRE)--Jan. 8, 2002--Immune Network Ltd.

> (OTCBB:IMMKF)(CDNX:IMM.) announced today the publication of results

> with its 1F7 antibody in tests designed to find out whether it may be

> able to improve the response of the immune system to infection.

>

> The 1F7 antibody is thought to have specific reactivity with

> antibodies from both the human immunodeficiency (HIV) and the

> hepatitis C (HCV) viruses.

>

> " As others have previously demonstrated for HIV, we now show that

> antibodies against HCV share a common structural feature recognized

> by 1F7, " said Dr. Grant, a member of the immunology research

> group in the Faculty of Medicine at Memorial University in Canada and

> collaborator with Immune Network. " It's reasonable to speculate that

> antibodies produced in other chronic diseases share the same

> features. " Dr. Grant has shown that 1F7 selectively binds antibodies

> against multiple components of HCV in addition to previous studies

> showing the binding of 1F7 to anti-HIV antibodies. This is exciting

> news, since it means that 1F7 has the potential to boost the human

> immune system when either or both infections are present. Further

> work is planned with 1F7 to test for its reactivity with antibodies

> to other viruses causing chronic infections, to further establish its

> mechanism of action, and to develop it as a potential human

> therapeutic drug.

>

> The Journal of Medical Virology published Dr. Grant's work under the

> title " Antibody Convergence Along a Common Idiotypic Axis in

> Immunodeficiency Virus and Hepatitis C Virus Infections " in its

> January issue. The abstract can be viewed on the World Wide Web at

> http://www3.interscience.wiley.com/cgi-bin/abstract/88511251/START .

> Copies of the abstract and the complete publication can also be

> obtained from Immune Network. This work was funded by Immune Network

> and by the Canadian Institute for Health Research.

>

> More about 1F7:

>

> Monoclonal antibody 1F7 has profound effects on the function of the

> immune system and the action of immune cells. Numerous publications

> suggest that 1F7 may be able to extend the ability of the immune

> system to generate antibodies against HIV, even after the virus

> mutates, possibly preventing the virus from " escaping " from the

> immune system. Other data from Dr. Grant's laboratory, published in

> Immunology and Cell Biology in February 2000, demonstrated that 1F7

> had specific effects on human immune cells (CTL cells) from HIV

> infected patients to prevent these cells from killing other immune

> cells (uninfected helper T cells).

>

> If the beneficial effects of 1F7 on the immune system can be

> confirmed, it would be an important new approach to the treatment of

> HIV infection and AIDS. Now, with the demonstration that 1F7 has

> activity that could have an impact on other chronic viral diseases

> such as HCV, the relevance of accelerating the development of 1F7 is

> evident. Immune Network is forming a team in 2002 to develop a plan

> for the clinical evaluation and future commercialization of this

> product as well as that of another Immune Network anti-HIV antibody,

> hNM01. Further information on these products and the team working on

> them will be available later in this quarter.

>

> On behalf of the Board of Directors

> Bain, Ph.D., CEO

>

> " Safe Harbor " Statement under the Private Securities Litigation

> Reform Act of 1995:

>

> This news release contains forward looking statements that are not

> historical facts and are subject to risks and uncertainties which

> could cause actual results to differ materially from those set forth

> in or implied herein. These risks are described in detail in the

> company's Securities and Exchange Commission filings.

>

> The Canadian Venture Exchange has not reviewed and does not accept

> responsibility for the adequacy or accuracy of the content of this

> news release.

>

> CONTACT:

> Immune Network Ltd.

> Investor Relations, 604/222-5541

> or 1-877/644-5541 ext. 466

> Fax: 604/222-5542

> E-mail: info@...

> Website: www.immunenetwork.com

>

> __________________________________________________

>